Is Euflexxa a Steroid?

Euflexxa is a hyaluronic acid-based viscosupplement used to relieve knee pain associated with osteoarthritis. One common question patients ask is, “Is Euflexxa a steroid?” The answer is no. Unlike corticosteroid injections, Euflexxa supplements the hyaluronic acid naturally found in joint fluid, helping improve lubrication and cushioning without relying on steroid medication.

Corticosteroids primarily relieve arthritis symptoms by suppressing inflammation, but repeated or inappropriate use may carry significant risks. Euflexxa works differently: it is injected into the affected knee to restore the properties of synovial fluid, support smoother joint movement, and provide gradual relief without the systemic effects typically associated with steroid treatment.

This article explains how Euflexxa is classified, how its mechanical and biochemical actions differ from those of corticosteroids, and what these differences may mean for treatment safety and long-term osteoarthritis management.

Key Takeaways

• Euflexxa is not a steroid; it is a Class III medical device regulated by the FDA, specifically a hyaluronic acid-based viscosupplement that treats knee osteoarthritis through combined mechanical and biochemical actions.
• Unlike corticosteroids, Euflexxa provides joint relief primarily by enhancing lubrication, cushioning, and restoring the viscosity of natural synovial fluid, rather than by suppressing inflammation chemically.
• Recent studies have recognized that Euflexxa also offers significant biochemical benefits, including the reduction of inflammatory mediators and the potential protection of joint cartilage health over time.
• Euflexxa has a favorable long-term safety profile, free from systemic side effects commonly associated with repeated steroid injections, including cartilage thinning and hormonal disruptions.
• Clinicians often adopt a combined treatment strategy, initially using corticosteroids for rapid symptom control, followed by a transition to Euflexxa for sustained joint management and long-term protection.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and a range of medical and aesthetic products for your practice. We offer authentic products from leading brands at the lowest prices. Contact Doctor Medica today!

Recommended products

EUFLEXXA® 10mg/ml

$209.00

Add to cart Adding...

Is Euflexxa a Steroid? Product Classification and Clinical Differentiation

When evaluating treatment options for knee osteoarthritis (OA), it’s crucial to differentiate clearly between products like Euflexxa and traditional steroid injections, not only regarding their mechanisms of action but also their regulatory classification.[2] Patients frequently ask if viscosupplements such as Euflexxa are considered drugs, and this distinction affects prescription practices and anticipated side effects.

Contrary to corticosteroids, Euflexxa is not a pharmaceutical drug. In the United States, both Euflexxa and Synvisc are classified as Class III medical devices, subject to rigorous premarket approval (PMA) by the FDA under 21 CFR 888.3569 and PMA P010029. 

Similarly, in the European Union, injectable hyaluronic acid (HA) products like Euflexxa and Synvisc also fall under the strict regulatory oversight of the Medical Device Regulation (MDR), classified as Class III devices due to their invasive use and risk profile (Annex VIII, Rules 8–9).

Comparing Euflexxa to Other HA-Based Injections & Corticosteroids

Feature	Euflexxa	Synvisc	Corticosteroids (e.g., Kenalog)
Classification	Class II medical device	Class III medical device	Pharmaceutical drug
Active Ingredient	Sodium hyaluronate (non-avian origin)	Hylan G-F 20 (avian-derived, cross-linked HA)	Triamcinolone, methylprednisolone, etc.
Mechanism of Action	Mechanical lubrication, shock absorption	Mechanical + some anti-inflammatory potential	Suppresses immune/inflammatory response
Steroid Content	None	None	Yes
Onset of Relief	Gradual (weeks)	Moderate (often faster than Euflexxa)	Rapid (within days)
Regulatory Oversight	FDA-cleared device	FDA-cleared device	FDA-approved drug

As the Euflexxa vs Synvisc comparison shows, although both are steroid-free viscosupplements, they differ significantly in molecular origin, cross-linking, and biochemical interactions within the joint. 

Euflexxa, derived from non-avian sources, typically carries a lower allergy risk, while Synvisc might provide quicker relief but higher immunogenic potential. Corticosteroids, while helpful for immediate inflammatory relief, have limited suitability for prolonged treatment due to systemic risks.

Understanding these classifications and regulatory contexts, particularly in light of the ongoing FDA review initiated in 2018 regarding HA product categorization, enables clinicians to make more informed treatment choices that prioritize patient safety and clinical efficacy.

Mechanism: Mechanical vs Biochemical Action

Understanding how Euflexxa functions involves recognizing its dual-action mechanism—both mechanical and biochemical. This combination distinguishes it from corticosteroids, which rely predominantly on biochemical, anti-inflammatory pathways.

Mechanical Action

Primarily, Euflexxa enhances the mechanical properties of joint fluid:

• Improves viscosity and lubrication, closely mimicking the body’s natural synovial fluid.
  
• Cushions the joint, reducing friction between cartilage surfaces.
  
• Enhances shock absorption, protecting the joint during movement and physical activity.

By physically restoring joint fluid characteristics, Euflexxa provides immediate mechanical support, aiding smoother, less painful joint movement without systemic immunosuppressive effects.

Biochemical Action

Recent research highlights that hyaluronic acid injections, including Euflexxa, also demonstrate significant biochemical effects within the joint:

• Modulates inflammatory pathways, potentially reducing inflammatory mediators within joint tissues.
  
• Protects cartilage health by promoting chondrocyte viability and reducing cartilage-degrading enzymes.
  
• Stimulates the joint’s own production of hyaluronic acid, contributing to sustained joint function and comfort over time.

Although initially recognized primarily for its mechanical support, the biochemical contributions of Euflexxa substantially enhance its therapeutic value, making it beneficial for the management of chronic osteoarthritis.

Comparison to Corticosteroids

In contrast, corticosteroids like Kenalog and Depo-Medrol focus mainly on biochemical actions by:

• Rapidly suppressing inflammatory responses.
  
• Blocking immune cell activation and cytokine release.
  
• Providing swift relief during acute osteoarthritis flare-ups.

However, corticosteroids do not provide mechanical joint support and may carry significant side effects with repeated use, including cartilage thinning and systemic hormonal imbalances.

Clinical Implications

Clinicians should consider both mechanical and biochemical benefits of Euflexxa when planning treatments. This comprehensive approach may offer:

• Gradual but sustained symptom relief.
  
• Improved joint protection over time.
  
• Reduced long-term systemic risks compared to steroid injections.

This balanced mechanism underscores why Euflexxa is often a preferred long-term therapy in the management of knee osteoarthritis.[3]

Safety Profile vs Corticosteroids

Safety remains a critical concern when considering treatments for chronic knee osteoarthritis. While corticosteroids provide immediate anti-inflammatory benefits, frequent use carries documented risks, prompting many clinicians and patients to consider longer-term alternatives such as Euflexxa. This distinction is central to answering the question, “Is Euflexxa a steroid?” and understanding why its mechanism and safety profile differ from those of corticosteroid treatments.

Cartilage Health

• Corticosteroids: Repeated injections can accelerate cartilage thinning, potentially worsening OA progression.
  
• Euflexxa: Does not degrade cartilage; research suggests potential protective effects on joint integrity.

Systemic Side Effects

• Corticosteroids: Systemic corticosteroids can carry serious risks even when used for a short period. In a large population-based study, adults prescribed oral corticosteroids for fewer than 30 days had higher rates of sepsis, venous thromboembolism, and fracture, particularly within the first 30 days after treatment.[1]
  
• Euflexxa: Primarily causes localized adverse effects, such as temporary pain or swelling in the treated joint.

The Waljee study evaluated short-term oral corticosteroids rather than corticosteroid injections administered directly into the knee. Its findings provide context about systemic steroid risks but should not be interpreted as direct evidence about the safety of intra-articular corticosteroid injections.[1]

Injection Frequency and Tissue Health

• Corticosteroids: Generally limited to 3–4 injections annually due to safety concerns (skin thinning, pigment changes, infection risks).
  
• Euflexxa: Safely administered every six months, aligning with a consistent and safer long-term OA management strategy.

While corticosteroids are valuable for immediate relief, Euflexxa provides a preferable safety profile for long-term joint management.

Treatment Strategy and Patient Implications

Choosing between Euflexxa and corticosteroids ultimately hinges on individual patient needs, clinical severity, and treatment objectives. Corticosteroids may be appropriate for rapid inflammation reduction during acute OA flares, whereas Euflexxa is suited to ongoing management, protecting joint health without systemic adverse effects.

A combined treatment approach is often employed: corticosteroids initially to rapidly control severe symptoms, followed by transitioning to Euflexxa for longer-term maintenance therapy. Such a dual-phase strategy helps balance immediate symptom relief and sustained joint function improvement, promoting lasting mobility and quality of life.

Clinicians and patients should jointly discuss:

• Symptom urgency vs. long-term health considerations.
  
• Allergy profiles (favoring Euflexxa’s non-avian composition).
  
• Scheduling constraints and preferred treatment frequency.

Conclusion

Understanding the answer to “Is Euflexxa a steroid?” can help patients and clinicians make clearer treatment comparisons. Euflexxa is a viscosupplement rather than a corticosteroid, giving it a different mechanism of action and safety profile. By supplementing the hyaluronic acid in the knee joint, it may improve lubrication, cushioning, and mobility without relying on steroid medication.

For optimal treatment planning, patients should discuss with their healthcare providers whether Euflexxa, corticosteroids, or a thoughtfully combined therapeutic strategy aligns best with their individual OA management goals.

FAQs

1. Does Euflexxa reduce inflammation like steroids?

No, Euflexxa works mechanically by moisturizing and cushioning the joint. It doesn’t chemically suppress inflammation like corticosteroids do.

2. How often can I get Euflexxa injections?

Following the standard Euflexxa dosage, you may receive three injections one week apart and repeat the series every six months as needed.

3. Can I have steroid and Euflexxa injections together?

Yes—some doctors use a steroid injection for immediate pain relief, followed by Euflexxa to maintain joint health. Discuss timing and safety with your provider.

4. Are there side effects from Euflexxa?

Mild joint swelling, pain, or warmth at the injection site may occur, but systemic side effects common with steroids are not expected. 

Citations

[1] Waljee, Akbar K et al. “Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.” BMJ (Clinical research ed.) vol. 357 j1415. 12 Apr. 2017, doi:10.1136/bmj.j1415

[2] Shmerling, Robert H. “A New Look at Steroid Injections for Knee and Hip Osteoarthritis.” Harvard Health Publishing, 17 Apr. 2020, www.health.harvard.edu/blog/a-new-look-at-steroid-injections-for-knee-and-hip-osteoarthritis-2019122318430.

[3] Brincat, Clarissa. “Knee Osteoarthritis: Are Steroid Injections or Hyaluronic Acid Better?” Medical News Today, 30 Nov. 2022, www.medicalnewstoday.com/articles/knee-osteoarthritis-are-steroid-injections-or-hyaluronic-acid-better.